SRR1335064
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.444
- INFLAMMATORY_RESPONSE+0.422
- COAGULATION+0.394
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.358
- KRAS_SIGNALING_UP+0.294
- ALLOGRAFT_REJECTION+0.288
- PANCREAS_BETA_CELLS+0.254
- MYOGENESIS+0.252
- ANGIOGENESIS+0.240
- IL6_JAK_STAT3_SIGNALING+0.217
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.570
- MYC_TARGETS_V1-0.559
- MYC_TARGETS_V2-0.554
- DNA_REPAIR-0.519
- UNFOLDED_PROTEIN_RESPONSE-0.519
- PROTEIN_SECRETION-0.501
- MTORC1_SIGNALING-0.449
- CHOLESTEROL_HOMEOSTASIS-0.381
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.353
- HEDGEHOG_SIGNALING-0.352
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1476614 | GTEX | — | 0.960 |
| 2 | SRR1418604 | GTEX | — | 0.955 |
| 3 | SRR1499823 | GTEX | — | 0.955 |
| 4 | SRR1389348 | GTEX | — | 0.948 |
| 5 | SRR614515 | GTEX | — | 0.948 |
| 6 | SRR661433 | GTEX | — | 0.946 |
| 7 | SRR655590 | GTEX | — | 0.945 |
| 8 | SRR1459423 | GTEX | — | 0.944 |
| 9 | SRR1320012 | GTEX | — | 0.942 |
| 10 | SRR1444559 | GTEX | — | 0.941 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.444 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.422 | Idelalisib | — uncovered |
| COAGULATION | 0.394 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.358 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.294 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.288 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.254 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.252 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.217 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.212 | Inavolisib | — uncovered |
| COMPLEMENT | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.172 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.162 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.144 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.135 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.036 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.034 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.028 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.004 | Idelalisib | — uncovered |